1
|
Robinson BW, Musk AW and Lake RA:
Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tsao AS, Wistuba I, Roth JA and Kindler
HL: Malignant pleural mesothelioma. J Clin Oncol. 27:2081–2090.
2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Vogelzang NJ: Chemotherapy for malignant
pleural mesothelioma. Lancet. 371:1640–1642. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Goudar RK: New therapeutic options for
mesothelioma. Curr Oncol Rep. 7:260–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
5
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
6
|
Frisch SM and Francis H: Disruption of
epithelial cell-matrix interactions induces apoptosis. J Cell Biol.
124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI
|
7
|
Meredith JE Jr, Fazeli B and Schwartz MA:
The extracellular matrix as a cell survival factor. Mol Biol Cell.
4:953–961. 1993. View Article : Google Scholar : PubMed/NCBI
|
8
|
Cohen GM: Caspases: The executioners of
apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
9
|
Valentijn AJ, Zouq N and Gilmore AP:
Anoikis. Biochem Soc Trans. 32:421–425. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
de Ridder L, Cornelissen M and de Ridder
D: Autologous spheroid culture: A screening tool for human brain
tumour invasion. Crit Rev Oncol Hematol. 36:107–122. 2000.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Simpson CD, Anyiwe K and Schimmer AD:
Anoikis resistance and tumor metastasis. Cancer Lett. 272:177–185.
2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhong X and Rescorla FJ: Cell surface
adhesion molecules and adhesion-initiated signaling: Understanding
of anoikis resistance mechanisms and therapeutic opportunities.
Cell Signal. 24:393–401. 2012. View Article : Google Scholar
|
13
|
Mueller-Klieser W: Three-dimensional cell
cultures: From molecular mechanisms to clinical applications. Am J
Physiol. 273:C1109–C1123. 1997.PubMed/NCBI
|
14
|
Daubriac J, Fleury-Feith J, Kheuang L,
Galipon J, Saint-Albin A, Renier A, Giovannini M, Galateau-Sallé F
and Jaurand MC: Malignant pleural mesothelioma cells resist anoikis
as quiescent pluricellular aggregates. Cell Death Differ.
16:1146–1155. 2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yeatman TJ: A renaissance for SRC. Nat
Revc Cancer. 4:470–480. 2004. View
Article : Google Scholar
|
17
|
Eguchi R, Kubo S, Takeda H, Ohta T, Tabata
C, Ogawa H, Nakano T and Fujimori Y: Deficiency of Fyn protein is
prerequisite for apoptosis induced by Src family kinase inhibitors
in human mesothelioma cells. Carcinogenesis. 33:969–975. 2012.
View Article : Google Scholar : PubMed/NCBI
|
18
|
Arai K, Sakamoto R, Kubota D and Kondo T:
Proteomic approach toward molecular backgrounds of drug resistance
of osteosarcoma cells in spheroid culture system. Proteomics.
13:2351–2360. 2013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Eguchi R, Kubo S, Ohta T, Kunimasa K,
Okada M, Tamaki H, Kaji K, Wakabayashi I, Fujimori Y and Ogawa H:
FK506 induces endothelial dysfunction through attenuation of Akt
and ERK1/2 independently of calcineurin inhibition and the caspase
pathway. Cell Signal. 25:1731–1738. 2013. View Article : Google Scholar : PubMed/NCBI
|
20
|
Eguchi R, Fujimori Y, Ohta T, Kunimasa K
and Nakano T: Calpain is involved in cisplatin-induced endothelial
injury in an in vitro three-dimensional blood vessel model. Int J
Oncol. 37:1289–1296. 2010.PubMed/NCBI
|
21
|
Eguchi R, Fujimori Y, Takeda H, Tabata C,
Ohta T, Kuribayashi K, Fukuoka K and Nakano T: Arsenic trioxide
induces apoptosis through JNK and ERK in human mesothelioma cells.
J Cell Physiol. 226:762–768. 2011. View Article : Google Scholar
|
22
|
Carduner L, Picot CR, Leroy-Dudal J, Blay
L, Kellouche S and Carreiras F: Cell cycle arrest or survival
signaling through αv integrins, activation of PKC and ERK1/2 lead
to anoikis resistance of ovarian cancer spheroids. Exp Cell Res.
320:329–342. 2014. View Article : Google Scholar
|
23
|
McCarroll JA, Gan PP, Erlich RB, Liu M,
Dwarte T, Sagnella SS, Akerfeldt MC, Yang L, Parker AL, Chang MH,
et al: TUBB3/βIII-tubulin acts through the PTEN/AKT signaling axis
to promote tumorigenesis and anoikis resistance in non-small cell
lung cancer. Cancer Res. 75:415–425. 2015. View Article : Google Scholar
|
24
|
Datta SR, Brunet A and Greenberg ME:
Cellular survival: A play in three Akts. Genes Dev. 13:2905–2927.
1999. View Article : Google Scholar : PubMed/NCBI
|
25
|
Diaz-Montero CM, Wygant JN and McIntyre
BW: PI3-K/Akt-mediated anoikis resistance of human osteosarcoma
cells requires Src activation. Eur J Cancer. 42:1491–1500. 2006.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Barbone D, Yang TM, Morgan JR, Gaudino G
and Broaddus VC: Mammalian target of rapamycin contributes to the
acquired apoptotic resistance of human mesothelioma multicellular
spheroids. J Biol Chem. 283:13021–13030. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Liao J, Qian F, Tchabo N,
Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB,
Morrison CD, et al: Ovarian cancer spheroid cells with stem
cell-like properties contribute to tumor generation, metastasis and
chemotherapy resistance through hypoxia-resistant metabolism. PLoS
One. 9:e849412014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Dudek AZ, Pang H, Kratzke RA, Otterson GA,
Hodgson L, Vokes EE and Kindler HL; Cancer and Leukemia Group B:
Phase II study of dasatinib in patients with previously treated
malignant mesothelioma (cancer and leukemia group B 30601): a brief
report. J Thorac Oncol. 7:755–759. 2012. View Article : Google Scholar : PubMed/NCBI
|